deltatrials
Terminated PHASE3 NCT00124930

Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

Sponsor: Alberta Health services

Conditions Nausea Neoplasms
Interventions Haldol Olanzapine
Updated 6 times since 2017 Last updated: Jan 18, 2012 Started: May 31, 2005 Primary completion: Jun 30, 2008 Completion: Jun 30, 2008

A PHASE3 clinical study on Nausea and Neoplasms, this trial is terminated or withdrawn. The trial is conducted by Alberta Health services and has accumulated 6 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Oct 2022 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jan 2021 — Oct 2022 [monthly]

    Terminated PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE3

    First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alberta Health services
  • Canadian Institutes of Health Research (CIHR)
Data source: AHS Cancer Control Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Calgary, Canada